Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    

| More

Maintain ADD on Sun Pharma - Specialty scale up delayed - HDFC Securities

Posted On: 2020-05-28 17:31:47

Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Sun Pharma (Q4FY20): Specialty scale up delayed. Maintain ADD
(TP Rs 480, CMP Rs 451, MCap Rs 1, 082 bn)

Sun's Q4 EBIDTA/PAT missed expectations on account of higher costs and certain one off expenses. US business (ex Taro) was largely stable. The ramp up in global specialty business was encouraging (+7% QoQ) led by traction in Ilumya, Yonsa and Cequa, however, the outlook for FY21 remains sluggish. Specialty related costs will remain elevated whereas ramp up in revenues may get delayed exacerbated by Covid led challenges. On the other hand, Sun's balance sheet continue to remain strong with increased focus on cash conservation (repaid ~USD400mn debt in FY20) and cash collection during uncertain times. We maintain Add rating with revised TP of Rs480.

In line revenues, margins disappoint: Q4 revenues at Rs 81.5bn (+15% YoY, flat QoQ, low base) were largely in line. EBIDTA margin at 18.4% were below expectation (down 319bps QoQ) led by lower gross margin (down 118bps YoY, Taro led, product mix) coupled with higher employee cost (+119bps QoQ, incentives provision) and higher other expenses (+81bps QoQ, specialty costs). Adjusted for one off expenses (Rs2.6bn) and forex loss (Rs1.4bn), PAT stood at Rs80.3bn (19% miss).

Covid may dent near term outlook for specialty business: Sun's specialty business (USD126mn) grew by 7% QoQ led by improved traction in Ilumya, Cequa and Yonsa. Ilumya reported revenues of USD94mn (including royalty/licensing income) for FY20. The product's advantage (lower dosing frequency, better safety profile) over peers should prove to be beneficial in the longer term; however, scale up in the near term needs to be monitored. For Cequa, while the TRx have declined post Coivd, Sun has been able to maintain its market share.

India business to grow in line with the industry: Sun's Q4 growth at 8% YoY was in line with estimates. Sun expects Q1FY21 to be challenging for the entire industry. While chronic segment continues to see momentum, acute and semi-chronic segments remain most impacted.

Key call takeaways: a) Global specialty sales at USD126mn, specialty R&D at 24% of overall R&D in Q4; b) Debt repayment - ~USD400mn in FY20, expect similar reduction in FY21; c) Halol resolution- FDA has alternate guidelines to inspect facilities; c) SEBI probe - no further update; d) US generics - price erosion continues, expects product flow to aid base business, Pending ANDA - 98, NDA - 5; e) R&D - expects to inch up to 7-8% of sales.

Maintain Add, risks: We increase our TP to Rs480 based on 21x FY22e EPS in line with peers. Key risks: Delay in resolution of Halol 483s, higher price erosion in the US, lower growth in the India business, slower ramp up in specialty, adverse outcome on ongoing SEBI probe on whistle-blower complaint, DOJ investigation, and drug price fixing lawsuit in the US.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.459.25 as compared to the previous close of Rs. 450.55. The total number of shares traded during the day was 332089 in over 7515 trades.

The stock hit an intraday high of Rs. 461.8 and intraday low of 444.75. The net turnover during the day was Rs. 151327616.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Real Estate (Sector Update) - Greenshoots visible - HDFC Securities

Cement (Sector Update) - Prices, retail sales hold up despite COVID - HDFC Securities

TCI Express - Branch economics, cost levers as margin tailwinds - ICICI Securities

Mishra Dhatu Nigam - Space order inflow may slow down in FY21 - ICICI Securities

Century Plyboards - Compelling BUY; top pick in building materials - ICICI Securities

Building material - Sector Update - ICICI Securities

ISGEC Heavy Engineering - On a strong footing despite macro headwinds - ICICI Securities

Telecom - Growth breaks due to Covid-19 crisis - ICICI Securities

Pfizer Ltd - Company Update - ICICI Securities

Petronet LNG - Quant Pick - ICICI Securities

Earnings Wrap Q4FY20: Quarter end lockdown takes toll, one-offs rule Q4FY20

Autos & Transportation Sector Update Report - Focus on '3Cs' - HDFC Securities

Banking Sector Credit Trends - Weakness building - HDFC Securities

India Equity Strategy Report - Back to pre-covid levels - HDFC Securities

Strategy: Cyclicals to lead earnings recovery over FY20-22 - ICICI Securities

JK Cement - Ripe for re-rating - ICICI Securities

Phillips Carbon Black - Company Update - ICICI Securities

Information Technology - Q1FY21 Result Preview - ICICI Securities

Motherson Sumi Systems Ltd - Company Update - ICICI Securities

HDFC Ltd - Quant Pick - ICICI Securities

Auto Sales Data for June 2020 - Angel Broking

FMCG - Sector Review 4QFY20 - Disruption visible, growth divergence increases - HDFC Securities

Maintain ADD on ONGC - Impairment loss drags earnings - HDFC Securities

Maintain BUY on Ahluwalia Contracts - Looking ahead - HDFC Securities

RIL-Intel Deal - Angel Broking

Strategy: 'Out of turn' change in NIFTY50 due to Vedanta delisting - ICICI Securities

Time Technoplast - Q4FY20 Result Update - ICICI Securities

Monthly Auto Volumes - July 2020 - ICICI Securities

Oil & Natural Gas Corporation - Q4FY20 Result Update - ICICI Securities

Minda Industries - Q4 FY20 Result Update - ICICI Securities

Auto Sales - June 2020 - Acuité Ratings & Research

Bharat Electronics - Q4FY20 Result Update - ICICI Securities

Petronet LNG - Q4FY20 Result Update - ICICI Securities

Tata Steel - Q4FY20 Result Update - ICICI Securities

Phoenix Mills - Q4FY20 Result Update - ICICI Securities

Jun-20 Volumes expectations: Sales to rise over 2x from May-20 levels for Hero, Maruti - HDFC Securities

Maintain REDUCE on RBL Bank - Risks more evident - HDFC Securities

Maintain ADD on Subros - Expect market share gains to continue - HDFC Securities

Maintain ADD on Petronet LNG - One offs in opex drag profitability - HDFC Securities

Siyaram Silk Mills - Company Update - ICICI Securities

Vardhman Textiles - Company Update - ICICI Securities

Bharat Forge - Q4FY20 Result Update - ICICI Securities

CESC - Q4FY20 Result Update - ICICI Securities

Star Cement - Company Update - ICICI Securities

BUY on GIC Reinsurance - Arduous Road Ahead - HDFC Securities

ADD on Oil India - Excess provisions drag EBITDA - HDFC Securities

Maintain BUY on Sobha - Well placed for recovery - HDFC Securities

Maintain REDUCE on Emami - Miss on all fronts - HDFC Securities

BUY on Galaxy Surfactants - Higher per unit EBITDA leads profitability - ICICI Securities

Maintain BUY on J. Kumar Infraprojects - Migration headwinds - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019